3/120
0.1 / 5 stars
All 120 Win/Lose results shown below
MAZE Roast Me summary
Maze Therapeutics, Inc. (MAZE). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseMAZE / S&P -0.03% / 15.20% |
LoseMAZE / S&P MAZE unavailable / 15.00% |
LoseMAZE / S&P MAZE unavailable / 50.40% |
| 2026-Q10/3 |
LoseMAZE / S&P -27.95% / -4.33% |
LoseMAZE / S&P MAZE unavailable / 11.30% |
LoseMAZE / S&P MAZE unavailable / 27.70% |
| 2025-Q41/3 |
WinMAZE / S&P 59.78% / 2.65% |
LoseMAZE / S&P MAZE unavailable / 9.00% |
LoseMAZE / S&P -344.00% / 13.40% |
| 2025-Q31/3 |
WinMAZE / S&P 111.33% / 8.12% |
LoseMAZE / S&P MAZE unavailable / 4.61% |
LoseMAZE / S&P MAZE unavailable / 13.45% |
| 2025-Q21/3 |
WinMAZE / S&P 11.44% / 10.94% |
LoseMAZE / S&P MAZE unavailable / 4.83% |
LoseMAZE / S&P MAZE unavailable / 10.63% |
| 2025-Q10/3 |
LoseMAZE / S&P MAZE unavailable / -4.27% |
LoseMAZE / S&P MAZE unavailable / 4.98% |
LoseMAZE / S&P MAZE unavailable / 10.57% |
| 2024-Q40/3 |
LoseMAZE / S&P MAZE unavailable / 2.41% |
LoseMAZE / S&P MAZE unavailable / 5.25% |
LoseMAZE / S&P MAZE unavailable / 6.15% |
| 2024-Q30/3 |
LoseMAZE / S&P MAZE unavailable / 5.89% |
LoseMAZE / S&P MAZE unavailable / 5.89% |
LoseMAZE / S&P MAZE unavailable / 6.11% |
| 2024-Q20/3 |
LoseMAZE / S&P MAZE unavailable / 4.28% |
LoseMAZE / S&P MAZE unavailable / 5.38% |
LoseMAZE / S&P MAZE unavailable / 5.12% |
| 2024-Q10/3 |
LoseMAZE / S&P MAZE unavailable / 10.56% |
LoseMAZE / S&P MAZE unavailable / 5.71% |
LoseMAZE / S&P MAZE unavailable / 5.59% |
| 2023-Q40/3 |
LoseMAZE / S&P MAZE unavailable / 11.69% |
LoseMAZE / S&P MAZE unavailable / 6.81% |
LoseMAZE / S&P MAZE unavailable / 7.78% |
| 2023-Q30/3 |
LoseMAZE / S&P MAZE unavailable / -3.27% |
LoseMAZE / S&P MAZE unavailable / 7.52% |
LoseMAZE / S&P MAZE unavailable / -5.03% |
| 2023-Q20/3 |
LoseMAZE / S&P MAZE unavailable / 8.74% |
LoseMAZE / S&P MAZE unavailable / 9.50% |
LoseMAZE / S&P MAZE unavailable / -8.57% |
| 2023-Q10/3 |
LoseMAZE / S&P MAZE unavailable / 7.50% |
LoseMAZE / S&P MAZE unavailable / 10.77% |
LoseMAZE / S&P MAZE unavailable / -15.69% |
| 2022-Q40/3 |
LoseMAZE / S&P MAZE unavailable / 7.56% |
LoseMAZE / S&P MAZE unavailable / 11.88% |
LoseMAZE / S&P MAZE unavailable / -17.99% |
| 2022-Q30/3 |
LoseMAZE / S&P MAZE unavailable / -4.88% |
LoseMAZE / S&P MAZE unavailable / 13.47% |
LoseMAZE / S&P MAZE unavailable / -1.41% |
| 2022-Q20/3 |
LoseMAZE / S&P MAZE unavailable / -16.10% |
LoseMAZE / S&P MAZE unavailable / 13.71% |
LoseMAZE / S&P MAZE unavailable / 11.04% |
| 2022-Q10/3 |
LoseMAZE / S&P MAZE unavailable / -4.60% |
LoseMAZE / S&P MAZE unavailable / 15.97% |
LoseMAZE / S&P MAZE unavailable / 42.23% |
| 2021-Q40/3 |
LoseMAZE / S&P MAZE unavailable / 11.03% |
LoseMAZE / S&P MAZE unavailable / 15.00% |
LoseMAZE / S&P MAZE unavailable / 96.40% |
| 2021-Q30/3 |
LoseMAZE / S&P MAZE unavailable / 0.58% |
LoseMAZE / S&P MAZE unavailable / 10.77% |
LoseMAZE / S&P MAZE unavailable / 69.42% |
| 2021-Q20/3 |
LoseMAZE / S&P MAZE unavailable / 8.55% |
LoseMAZE / S&P MAZE unavailable / 6.58% |
LoseMAZE / S&P MAZE unavailable / 51.81% |
| 2021-Q10/3 |
LoseMAZE / S&P MAZE unavailable / 6.17% |
LoseMAZE / S&P MAZE unavailable / -1.06% |
LoseMAZE / S&P MAZE unavailable / 7.39% |
| 2020-Q40/3 |
LoseMAZE / S&P MAZE unavailable / 12.15% |
LoseMAZE / S&P MAZE unavailable / -3.72% |
LoseMAZE / S&P MAZE unavailable / -33.42% |
| 2020-Q30/3 |
LoseMAZE / S&P MAZE unavailable / 8.93% |
LoseMAZE / S&P MAZE unavailable / -2.04% |
LoseMAZE / S&P MAZE unavailable / -27.10% |
| 2020-Q20/3 |
LoseMAZE / S&P MAZE unavailable / 20.54% |
LoseMAZE / S&P MAZE unavailable / -0.46% |
LoseMAZE / S&P MAZE unavailable / -27.11% |
| 2020-Q10/3 |
LoseMAZE / S&P MAZE unavailable / -19.60% |
LoseMAZE / S&P MAZE unavailable / 3.47% |
LoseMAZE / S&P MAZE unavailable / -14.75% |
| 2019-Q40/3 |
LoseMAZE / S&P MAZE unavailable / 9.07% |
LoseMAZE / S&P MAZE unavailable / 5.36% |
LoseMAZE / S&P MAZE unavailable / 2.99% |
| 2019-Q30/3 |
LoseMAZE / S&P MAZE unavailable / 1.70% |
LoseMAZE / S&P MAZE unavailable / 5.02% |
LoseMAZE / S&P MAZE unavailable / 0.21% |
| 2019-Q20/3 |
LoseMAZE / S&P MAZE unavailable / 4.30% |
LoseMAZE / S&P MAZE unavailable / 6.64% |
LoseMAZE / S&P MAZE unavailable / 8.65% |
| 2019-Q10/3 |
LoseMAZE / S&P MAZE unavailable / 13.65% |
LoseMAZE / S&P MAZE unavailable / 8.12% |
LoseMAZE / S&P MAZE unavailable / 14.29% |
| 2018-Q40/3 |
LoseMAZE / S&P MAZE unavailable / -13.52% |
LoseMAZE / S&P MAZE unavailable / 9.05% |
LoseMAZE / S&P MAZE unavailable / 18.23% |
| 2018-Q30/3 |
LoseMAZE / S&P MAZE unavailable / 7.71% |
LoseMAZE / S&P MAZE unavailable / 10.21% |
LoseMAZE / S&P MAZE unavailable / 19.06% |
| 2018-Q20/3 |
LoseMAZE / S&P MAZE unavailable / 3.43% |
LoseMAZE / S&P MAZE unavailable / 9.03% |
LoseMAZE / S&P MAZE unavailable / 14.46% |
| 2018-Q10/3 |
LoseMAZE / S&P MAZE unavailable / -0.76% |
LoseMAZE / S&P MAZE unavailable / 7.68% |
LoseMAZE / S&P MAZE unavailable / 12.46% |
| 2017-Q40/3 |
LoseMAZE / S&P MAZE unavailable / 6.64% |
LoseMAZE / S&P MAZE unavailable / 7.03% |
LoseMAZE / S&P MAZE unavailable / 13.82% |
| 2017-Q30/3 |
LoseMAZE / S&P MAZE unavailable / 4.48% |
LoseMAZE / S&P MAZE unavailable / 5.68% |
LoseMAZE / S&P MAZE unavailable / 17.57% |
| 2017-Q20/3 |
LoseMAZE / S&P MAZE unavailable / 3.09% |
LoseMAZE / S&P MAZE unavailable / 4.83% |
LoseMAZE / S&P MAZE unavailable / 17.74% |
| 2017-Q10/3 |
LoseMAZE / S&P MAZE unavailable / 6.07% |
LoseMAZE / S&P MAZE unavailable / 3.67% |
LoseMAZE / S&P MAZE unavailable / 13.32% |
| 2016-Q40/3 |
LoseMAZE / S&P MAZE unavailable / 3.82% |
LoseMAZE / S&P MAZE unavailable / 2.09% |
LoseMAZE / S&P MAZE unavailable / 7.05% |
| 2016-Q30/3 |
LoseMAZE / S&P MAZE unavailable / 3.85% |
LoseMAZE / S&P MAZE unavailable / 0.20% |
LoseMAZE / S&P MAZE unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | MAZE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 89.44% | 20.78% |
| Annualized return | 89.44% | 20.78% |
5Y · 2025-01-31 to 2026-08-28
| Metric | MAZE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 72.10% | 83.14% |
| Annualized return | 11.47% | 12.86% |
10Y · 2025-01-31 to 2026-08-28
| Metric | MAZE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 72.10% | 319.30% |
| Annualized return | 5.58% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |